Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Adoxa, Ascalan, Doxapress, Doxazosin, Hibadren, Prostadilat, Supressin; Bulgaria: Cardura, Doxazosin, Dozone, Kamiren, Zoxon; Cyprus: Cardura, Magurol, Prostazocin; Czech Republic: Cardura, Doxazosin, Dozone, Kamiren, Windoxa, Zoxon; Denmark: Cardosin, Carduran, Doxazosin; Estonia: Cardura, Doxalfa, Doxazosin, Doxonex, Kamiren, Tonocardin, Zoxon; France: Doxazosine, Zoxan; Germany: Alfamedil, Cardular, Diblocin, Doxa-Puren, Doxacor, Doxagamma, Doxamax, Doxanar, Doxazoflo, Doxazosin, Jutalar, Uriduct; Greece: Cardura, Maguran, Protectura; Hungary: Cardogen, Cardura, Doxagal, Doxazosin, Doxicard, Dozone; Ireland: Cardura, Carsem, Doxacar, Doxane, Doxatan, Doxel, Kamiren, Raporsin; Italy: Cardura, Dedralen, Doxazosin, Doxazosina; Latvia: Cardura, Doxagamma, Doxalfa, Doxazosin, Doxonex, Kamiren, Magurol, Tonocardin, Zoxon; Lithuania: Cardura, Doxalfa, Doxazosin, Doxonex, Kamiren, Tonocardin, Zoxon; Luxembourg: Doxazosine; Malta: Cardura, Doxazosin, Magurol; Netherlands: Cardura, Doxazosine; Poland: Alfamedin, Apo-Doxan, Cardura, Doksazosyna, Dosano, Doxagen, DoxaLEK, Doxanorm, Doxar, Doxaratio, Doxazosin, Doxonex, Dozone, Kamiren, Prostatic, Vaxosin, Zoxon; Portugal: Cardura, Doxazosina; Romania: Aniprosin, Cardura, Doxazosin, Hyxazin, Kamiren, Magurol, Zoxon; Slovakia: Cardura, Hyxazin, Kamiren, Magurol, Doxazosin, Doxonex, Dozone, Zoxon; Slovenia: Cardura, Doksazosin, Kamiren, Tonocardin; Spain: Carduran, Doxatensa, Doxazosina, Progandol; Sweden: Alfadil, Doserix, Doxastad, Doxazosin; UK: Cardura, Colixil, Doxadura, Doxazosin, Slocinx.

North America

Canada: Cardura, Doxazosin; USA: Cardura, Doxazosin.

Latin America

Argentina: Cardura, Doxasin, Doxazosina, Doxolbran, Lafedoxin, Prostazosina, Vazosin; Brazil: Carduran, Doxazosina, Unoprost, Zoflux; Mexico: Cardura.


Japan: Alflosin, Cademesin, Calmesosyn, Carbadogen, Cardenalin, Cardonan, Donashin, Doxazon, Doxazosin, Kazmarin, Platox M, Tatsuzosin.

Drug combinations


Doxazosin Mesylate: C~23~H~25~N~5~O~5~.CH~4~O~3~S. Mw: 547.58. (1) Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]-, monomethanesulfonate; (2) 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazine monomethanesulfonate. CAS-77883-43-3; CAS-74191-85-8 (doxazosin)(1981).

Pharmacologic Category

Cardiovascular Drugs; α-Adrenergic Blocking Agents. (ATC-Code: C02CA04).

Mechanism of action

Doxazosin is a quinazoline-derivative postsynaptic α~1~-adrenergic blocking agent. It reduces peripheral vascular resistance and blood pressure as a result of its vasodilating effects. The drug produces both arterial and venous dilation. Effects of doxazosin on the cardiovascular system are mediated by the drug’s activity at α~1~-receptor sites on vascular smooth muscle. Because of the prevalence of α-receptors on the prostate capsule, prostate adenoma, and the bladder trigone and the relative absence of these receptors on the bladder body, α-blockers decrease urinary outflow resistance in men. Doxazosin may improve to a limited extent the serum lipid profile and can reduce blood glucose and serum insulin concentrations. The drug does not appear to affect plasma renin activity appreciably.

Therapeutic use

Treatment of hypertension alone or in conjunction with diuretics, ACE inhibitors, β-blockers, or calcium antagonists. Treatment of urinary outflow obstruction and/or obstructive and irritative symptoms associated with BPH; can be used in combination with finasteride.

Pregnancy and lactiation implications

Embryolethality resulting from doxazosin exposure during organogenesis and delayed postnatal development reported. Use only if benefit outweighs risk. Use with caution in nursing women.

Unlabeled use


Hypersensitivity to quinazolines (prazosin, terazosin), doxazosin, or any component of the formulation.

Warnings and precautions

Discontinue if symptoms of angina occur or worsen. Intraoperative floppy iris syndrome observed in cataract surgery patients who were on or were previously treated with α~1~-blockers; causality not established. Can cause significant orthostatic hypotension and syncope, especially with first dose. Prostate cancer should be ruled out before beginning therapy. The extended release formulation consists of the drug within a nondeformable matrix (use of nondeformable products in stricture/narrowing of the GI tract associated with symptoms of obstruction). Use with caution in increased GI retention (e.g. chronic constipation) as doxazosin exposure may be increased. Extended release formulation is not approved for the treatment of hypertension. Possibility of doxazosin-induced postural dizziness. Priapism reported rarely. Use caution in impaired liver function or in patients who are receiving other agents (e.g. cimetidine) that could influence hepatic clearance of the drug (drug is almost completely metabolized in the liver). Use with caution in mild-to-moderate hepatic dysfunction. Not recommended in severe hepatic dysfunction.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart